Prevention of Relapse to Opioid Addiction Using Depot Naltrexone
The aim of this project is to conduct a multi-site effectiveness study to determine whether the addition of a monthly injection of depot naltrexone to treatment as usual (TAU) will significantly improve outcome in parolees and probationers with a history of opioid addiction compared to TAU alone. Participants will be randomized to either treatment as usual in community programs or monthly injections of depot naltrexone for six months with treatment as usual in community programs. The effectiveness of depot naltrexone has never been studied in opioid dependent parolees. all parolee subjects will be evaluated at baseline, while in treatment, and at 6, 12 and 18 month post entry time points. The primary study outcomes are retention in treatment, drug use, re-arrests, psychosocial and medical/psychiatric functioning, and economic costs and benefit costs of naltrexone.
NCT00781898 — Opiate Addiction
Status: Completed
http://inclinicaltrials.com/opiate-addiction/NCT00781898/
Impulsivity, Neural Deficits, and Relapse in Cocaine Addiction
The purpose of this study is to assess neurocognitive and associated neural regions/circuitry disruptions relevant to impulsive relapse in cocaine-addicted subjects, and the relationship of the cognitive and neural mechanisms of impulsivity/decision-making to relapse style.
NCT00744601 — Cocaine Dependence
Status: Completed
http://inclinicaltrials.com/cocaine-dependence/NCT00744601/
Project 1: Clinical Neurobiology of Serotonin and Addiction
The purpose of this study is to examine the relationship between 5-HT2R function, impulsivity and cue reactivity in cocaine dependent subjects and healthy controls and examine specific effects of escitalopram and mirtazapine on impulsivity and cue reactivity in human cocaine users.
NCT00732901 — Cocaine Dependence
Status: Completed
http://inclinicaltrials.com/cocaine-dependence/NCT00732901/
Dopamine Transporter (DAT) in Pharmacological Treatments of Cocaine Dependence. CAIMAN (Cocaine Addiction Imaging Medications and Neurotransmitters) Study
-Context: Study objectives Primary: impact of modafinil versus placebo on DAT density modifications in the striatal and extra-striatal regions in cocaine dependent subjects hospitalised from D3 to D21. Primary Hypothesis: More rapid normalisation of DAT concentrations measured by PET using modafinil versus placebo from D3 to D21 during cocaine detoxification.
NCT00701532 — Cocaine Dependence
Status: Completed
http://inclinicaltrials.com/cocaine-dependence/NCT00701532/
Cognitive Therapy for PTSD in Addiction Treatment
The purpose of this phase of the study is to assess the feasibility of a cognitive behavioral therapy for post-traumatic stress disorder (PTSD) in persons receiving outpatient services at an addiction treatment program. The next phase of the study will be a more rigorous investigation of the efficacy of the PTSD therapy within addiction treatment settings.
NCT00685451 — Substance-Related Disorders
Status: Completed
http://inclinicaltrials.com/substance-related-disorders/NCT00685451/
Clinical Trial of Topiramate for Cocaine Addiction
This is an outpatient clinical trial of topiramate for addressing cocaine dependence and reduction of cocaine associated behaviors in opiate dependent drug users maintained on methadone treatment. The study aims to answer whether topiramate 1. is safe and acceptable to methadone patients 2. reduces cocaine use 3. helps with collateral problems such as alcohol abuse, tobacco dependence, anxiety, PTSD and/or pain symptoms. The study will also evaluate topiramate effect on neuro-cognitive performance.
NCT00685178 — Cocaine Dependence
Status: Completed
http://inclinicaltrials.com/cocaine-dependence/NCT00685178/
Pregabalin Given to Tobacco Users to Study Addiction
The goal of this study is to examine the effects of a GABA (gamma amino butyric acid)-enhancing medication, pregabalin (300 mg/day), on smoking behavior, tobacco withdrawal and cigarette craving in smokers. We hypothesize that in smokers, pregabalin at 300 mg/day, will be more effective than placebo in decreasing smoking behavior and attenuating tobacco withdrawal and cigarette craving.
NCT00644137 — Nicotine Dependence
Status: Completed
http://inclinicaltrials.com/nicotine-dependence/NCT00644137/
Developing Computer Based Treatments for Addiction
The purpose of our research is to examine the promise of a new computer based approach to use in usual drug counseling when treating crack cocaine addiction.
NCT00586534 — Cocaine Addiction
Status: Completed
http://inclinicaltrials.com/cocaine-addiction/NCT00586534/
A Placebo-controlled, Double Blind, Randomized Trial of Acamprosate for the Treatment of Methamphetamine Dependence
This clinical trial will compare 10 week treatment with acamprosate (2 gr/day) versus placebo, combined with weekly abstinence oriented individual counseling, in methamphetamine dependent patients, 72 subjects will be enrolled, with an interim analysis scheduled after 36 enrolled. Primary outcome is methamphetamine absitience over the 10 week treatment period, and the last 2 weeks of treatment. Abstinence is defined on a weekly basis as no urine positive of methamphetamine (or amphetamine) and self-report of not use for the 7 day period. Secondary measures include treatment retention, drug craving, mood, and safety.
NCT00571922 — Methamphetamine Dependence, Treatment Seeking
Status: Completed
http://inclinicaltrials.com/methamphetamine-dependence-treatment-seeking/NCT00571922/
A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Two Dose Combinations of Metyrapone and Oxazepam in the Treatment of Cocaine Addiction
Subjects will be randomly assigned to receive either one of the two potential dose combinations of the study medications or placebo over 6 weeks. The study will include twice weekly visits to the research clinic for laboratory studies, safety assessments and urine drug screens. Subjects will also be questioned regarding drug craving and mood symptoms.
NCT00567814 — Cocaine Dependence
Status: Completed
http://inclinicaltrials.com/cocaine-dependence/NCT00567814/